Lymphocyte migration and multiple sclerosis: Relation with disease course and therapy

Annals of Neurology

Volumn 46, Issue 2, 1999, Pages 253-256

  Prat, Alexandre ^a,b   Al Asmi, Abdulla ^a   Duquette, Pierre ^b   Antel, Jack P ^a  

^a MCGILL UNIVERSITY   (Canada)

^b NOTRE DAME HOSPITAL   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

GLATIRAMER; INTERFERON BETA SERINE;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE COURSE; DRUG MECHANISM; HUMAN; HUMAN CELL; LYMPHOCYTE MIGRATION; MONONUCLEAR CELL; MULTIPLE SCLEROSIS; PRIORITY JOURNAL; RELAPSE; REMISSION;

EID: 0032838096     PISSN: 03645134     EISSN: None     Source Type: Journal    
DOI: 10.1002/1531-8249(199908)46:2<253::AID-ANA16>3.0.CO;2-C     Document Type: Article

References (17)

1. Nesbit GM, Forbes GS, Scheithauer BW, et al. Histopathologic and MR and CT correlation in 37 cases at biopsy and 3 cases at autopsy. Radiology 1991;180:467-474
2. Katz D, Taubenberger JK, Cannella B, et al. Correlation between MRI findings and lesions development in chronic active multiple sclerosis. Ann Neurol 1993;34:661-669
3. Yong VW, Krekosky CA, Forsyth PA, et al. Matrix metalloproteinases and diseases of the CNS. Trends Neurosci 1998;21: 75-80
4. Rosenberg GA, Dencoff JE, Correa N, et al. Effects of steroids on CSF matrix metalloproteinase in multiple sclerosis: relation to blood-brain barrier injury. Neurology 1996;46:1626-1632
5. Liedtke W, Cannella B, Mazzaccaro RJ, et al. Effective treatment of models of multiple sclerosis by matrix metalloproteinase inhibitors. Ann Neurol 1998;44:35-46
6. Leppert D, Waubant E, Burk MR, et al. Interferon-β1b inhibits gelatinase secretion and in vitro migration of human T cells: a possible mechanism for treatment efficacy in multiple sclerosis. Ann Neurol 1996;40:846-852
7. Thompson AJ, Kermode AG, Wicks D, et al. Major differences in the dynamics of primary and secondary progressive multiple sclerosis. Ann Neurol 1991;29:53-62
8. Stuve O, Dooley NP, Uhm JH, et al. Interferon-β1b decreases the migration of T lymphocytes in vitro: effects on matrix metalloproteinase-9. Ann Neurol 1996;40:853-863
9. Uhm JH, Dooley N, Stuve O, et al. Migratory behavior of T lymphocytes isolated from MS patients undergoing treatment with beta Interferon. Neurology 1997;48:A80 (Abstract)
10. Lublin FD, Reingold SC, National Multiple Sclerosis Society (USA) Advisory Committee on Clinical Trials of New Agents in Multiple Sclerosis. Defining the clinical course of multiple sclerosis: results of an international survey. Neurology 1996;46: 907-911
11. Leppert D, Ford J, Stabler G, et al. Matrix metalloproteinase-9 (gelatinase b) is selectively elevated in CSF during relapses and stable phase of multiple sclerosis. Brain 1998;121:2327-2334
12. Balashov KE, Khoury SJ, Hafler DA, Weiner HL. Inhibition of T cell responses by activated human CD8+ T cells is mediated by interferon gamma and is defective in chronic progressive multiple sclerosis. J Clin Invest 1995;95:2711-2719
13. Balashov KE, Smith DR, Khoury SJ, et al. Increased IL-12 production in progressive multiple sclerosis: induction by activated CD4+ T cells via CD40 ligand. Proc Natl Acad Sci USA 1997;94:599-603
14. Becher B, Giacomini PS, Pelletier D, et al. Interferon γ secretion by peripheral blood T-cell subsets in multiple sclerosis: correlation with disease phase and interferon β therapy. Ann Neurol 1999;45:247-250
15. Calabresi PA, Stone LA, Bash CN, et al. Interferon beta results in immediate reduction of contrast-enhanced lesions in multiple sclerosis patients followed by weekly MRI. Neurology 1997;48: 1446-1448
16. Mancardi GL, Sardanelli F, Parodi RC, et al. Effect of copolymer-1 on serial gadolinium-enhanced MRI in relapsing remitting multiple sclerosis. Neurology 1998;50:1127-1133
17. Lublin FD, Reingold SC. Combination therapy for treatment of multiple sclerosis. Ann Neurol 1998;44:7-9